The extended phenotype of LPS-responsive beige-like anchor protein (LRBA) deficiency
LPS-responsive beige-like anchor protein (LRBA) deficiency is a primary immunodeficiency caused by biallelic mutations in LRBA that abolish LRBA protein expression. We sought to report the extended phenotype of LRBA deficiency in a cohort of 22 LRBA-deficient patients. Clinical criteria, protein det...
Saved in:
Published in | Journal of allergy and clinical immunology Vol. 137; no. 1; pp. 223 - 230 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
01.01.2016
Elsevier Limited Elsevier |
Subjects | |
Online Access | Get full text |
ISSN | 0091-6749 1097-6825 1097-6825 |
DOI | 10.1016/j.jaci.2015.09.025 |
Cover
Loading…
Abstract | LPS-responsive beige-like anchor protein (LRBA) deficiency is a primary immunodeficiency caused by biallelic mutations in LRBA that abolish LRBA protein expression.
We sought to report the extended phenotype of LRBA deficiency in a cohort of 22 LRBA-deficient patients.
Clinical criteria, protein detection, and genetic sequencing were applied to diagnose LRBA deficiency.
Ninety-three patients met the inclusion criteria and were considered to have possible LRBA deficiency. Twenty-four patients did not express LRBA protein and were labeled as having probable LRBA deficiency, whereas 22 were genetically confirmed as having definitive LRBA deficiency, with biallelic mutations in LRBA. Seventeen of these were novel and included homozygous or compound heterozygous mutations. Immune dysregulation (95%), organomegaly (86%), recurrent infections (71%), and hypogammaglobulinemia (57%) were the main clinical complications observed in LRBA-deficient patients. Although 81% of LRBA-deficient patients had normal T-cell counts, 73% had reduced regulatory T (Treg) cell numbers. Most LRBA-deficient patients had low B-cell subset counts, mainly in switched memory B cells (80%) and plasmablasts (92%), with a defective specific antibody response in 67%. Of the 22 patients, 3 are deceased, 2 were treated successfully with hematopoietic stem cell transplantation, 7 are receiving immunoglobulin replacement, and 15 are receiving immunosuppressive treatment with systemic corticosteroids alone or in combination with steroid-sparing agents.
This report describes the largest cohort of patients with LRBA deficiency and offers guidelines for physicians to identify LRBA deficiency, supporting appropriate clinical management. |
---|---|
AbstractList | Background LPS-responsive beige-like anchor protein (LRBA) deficiency is a primary immunodeficiency caused by biallelic mutations in LRBA that abolish LRBA protein expression. Objective We sought to report the extended phenotype of LRBA deficiency in a cohort of 22 LRBA-deficient patients. Methods Clinical criteria, protein detection, and genetic sequencing were applied to diagnose LRBA deficiency. Results Ninety-three patients met the inclusion criteria and were considered to have possible LRBA deficiency. Twenty-four patients did not express LRBA protein and were labeled as having probable LRBA deficiency, whereas 22 were genetically confirmed as having definitive LRBA deficiency, with biallelic mutations in LRBA. Seventeen of these were novel and included homozygous or compound heterozygous mutations. Immune dysregulation (95%), organomegaly (86%), recurrent infections (71%), and hypogammaglobulinemia (57%) were the main clinical complications observed in LRBA-deficient patients. Although 81% of LRBA-deficient patients had normal T-cell counts, 73% had reduced regulatory T (Treg) cell numbers. Most LRBA-deficient patients had low B-cell subset counts, mainly in switched memory B cells (80%) and plasmablasts (92%), with a defective specific antibody response in 67%. Of the 22 patients, 3 are deceased, 2 were treated successfully with hematopoietic stem cell transplantation, 7 are receiving immunoglobulin replacement, and 15 are receiving immunosuppressive treatment with systemic corticosteroids alone or in combination with steroid-sparing agents. Conclusion This report describes the largest cohort of patients with LRBA deficiency and offers guidelines for physicians to identify LRBA deficiency, supporting appropriate clinical management. LPS-responsive beige-like anchor protein (LRBA) deficiency is a primary immunodeficiency caused by biallelic mutations in LRBA that abolish LRBA protein expression. We sought to report the extended phenotype of LRBA deficiency in a cohort of 22 LRBA-deficient patients. Clinical criteria, protein detection, and genetic sequencing were applied to diagnose LRBA deficiency. Ninety-three patients met the inclusion criteria and were considered to have possible LRBA deficiency. Twenty-four patients did not express LRBA protein and were labeled as having probable LRBA deficiency, whereas 22 were genetically confirmed as having definitive LRBA deficiency, with biallelic mutations in LRBA. Seventeen of these were novel and included homozygous or compound heterozygous mutations. Immune dysregulation (95%), organomegaly (86%), recurrent infections (71%), and hypogammaglobulinemia (57%) were the main clinical complications observed in LRBA-deficient patients. Although 81% of LRBA-deficient patients had normal T-cell counts, 73% had reduced regulatory T (Treg) cell numbers. Most LRBA-deficient patients had low B-cell subset counts, mainly in switched memory B cells (80%) and plasmablasts (92%), with a defective specific antibody response in 67%. Of the 22 patients, 3 are deceased, 2 were treated successfully with hematopoietic stem cell transplantation, 7 are receiving immunoglobulin replacement, and 15 are receiving immunosuppressive treatment with systemic corticosteroids alone or in combination with steroid-sparing agents. This report describes the largest cohort of patients with LRBA deficiency and offers guidelines for physicians to identify LRBA deficiency, supporting appropriate clinical management. Background LPS-responsive beige-like anchor protein (LRBA) deficiency is a primary immunodeficiency caused by biallelic mutations inLRBAthat abolish LRBA protein expression. Objective We sought to report the extended phenotype of LRBA deficiency in a cohort of 22 LRBA-deficient patients. Methods Clinical criteria, protein detection, and genetic sequencing were applied to diagnose LRBA deficiency. Results Ninety-three patients met the inclusion criteria and were considered to havepossibleLRBA deficiency. Twenty-four patients did not express LRBA protein and were labeled as havingprobableLRBA deficiency, whereas 22 were genetically confirmed as havingdefinitiveLRBA deficiency, with biallelic mutations inLRBA. Seventeen of these were novel and included homozygous or compound heterozygous mutations. Immune dysregulation (95%), organomegaly (86%), recurrent infections (71%), and hypogammaglobulinemia (57%) were the main clinical complications observed in LRBA-deficient patients. Although 81% of LRBA-deficient patients had normal T-cell counts, 73% had reduced regulatory T (Treg) cell numbers. Most LRBA-deficient patients had low B-cell subset counts, mainly in switched memory B cells (80%) and plasmablasts (92%), with a defective specific antibody response in 67%. Of the 22 patients, 3 are deceased, 2 were treated successfully with hematopoietic stem cell transplantation, 7 are receiving immunoglobulin replacement, and 15 are receiving immunosuppressive treatment with systemic corticosteroids alone or in combination with steroid-sparing agents. Conclusion This report describes the largest cohort of patients with LRBA deficiency and offers guidelines for physicians to identify LRBA deficiency, supporting appropriate clinical management. Background LPS-responsive beige-like anchor protein (LRBA) deficiency is a primary immunodeficiency caused by biallelic mutations in LRBA that abolish LRBA protein expression. Objective We sought to report the extended phenotype of LRBA deficiency in a cohort of 22 LRBA-deficient patients. Methods Clinical criteria, protein detection, and genetic sequencing were applied to diagnose LRBA deficiency. Results Ninety-three patients met the inclusion criteria and were considered to have possible LRBA deficiency. Twenty-four patients did not express LRBA protein and were labeled as having probable LRBA deficiency, whereas 22 were genetically confirmed as having definitive LRBA deficiency, with biallelic mutations in LRBA . Seventeen of these were novel and included homozygous or compound heterozygous mutations. Immune dysregulation (95%), organomegaly (86%), recurrent infections (71%), and hypogammaglobulinemia (57%) were the main clinical complications observed in LRBA-deficient patients. Although 81% of LRBA-deficient patients had normal T-cell counts, 73% had reduced regulatory T (Treg) cell numbers. Most LRBA-deficient patients had low B-cell subset counts, mainly in switched memory B cells (80%) and plasmablasts (92%), with a defective specific antibody response in 67%. Of the 22 patients, 3 are deceased, 2 were treated successfully with hematopoietic stem cell transplantation, 7 are receiving immunoglobulin replacement, and 15 are receiving immunosuppressive treatment with systemic corticosteroids alone or in combination with steroid-sparing agents. Conclusion This report describes the largest cohort of patients with LRBA deficiency and offers guidelines for physicians to identify LRBA deficiency, supporting appropriate clinical management. LPS-responsive beige-like anchor protein (LRBA) deficiency is a primary immunodeficiency caused by biallelic mutations in LRBA that abolish LRBA protein expression.BACKGROUNDLPS-responsive beige-like anchor protein (LRBA) deficiency is a primary immunodeficiency caused by biallelic mutations in LRBA that abolish LRBA protein expression.We sought to report the extended phenotype of LRBA deficiency in a cohort of 22 LRBA-deficient patients.OBJECTIVEWe sought to report the extended phenotype of LRBA deficiency in a cohort of 22 LRBA-deficient patients.Clinical criteria, protein detection, and genetic sequencing were applied to diagnose LRBA deficiency.METHODSClinical criteria, protein detection, and genetic sequencing were applied to diagnose LRBA deficiency.Ninety-three patients met the inclusion criteria and were considered to have possible LRBA deficiency. Twenty-four patients did not express LRBA protein and were labeled as having probable LRBA deficiency, whereas 22 were genetically confirmed as having definitive LRBA deficiency, with biallelic mutations in LRBA. Seventeen of these were novel and included homozygous or compound heterozygous mutations. Immune dysregulation (95%), organomegaly (86%), recurrent infections (71%), and hypogammaglobulinemia (57%) were the main clinical complications observed in LRBA-deficient patients. Although 81% of LRBA-deficient patients had normal T-cell counts, 73% had reduced regulatory T (Treg) cell numbers. Most LRBA-deficient patients had low B-cell subset counts, mainly in switched memory B cells (80%) and plasmablasts (92%), with a defective specific antibody response in 67%. Of the 22 patients, 3 are deceased, 2 were treated successfully with hematopoietic stem cell transplantation, 7 are receiving immunoglobulin replacement, and 15 are receiving immunosuppressive treatment with systemic corticosteroids alone or in combination with steroid-sparing agents.RESULTSNinety-three patients met the inclusion criteria and were considered to have possible LRBA deficiency. Twenty-four patients did not express LRBA protein and were labeled as having probable LRBA deficiency, whereas 22 were genetically confirmed as having definitive LRBA deficiency, with biallelic mutations in LRBA. Seventeen of these were novel and included homozygous or compound heterozygous mutations. Immune dysregulation (95%), organomegaly (86%), recurrent infections (71%), and hypogammaglobulinemia (57%) were the main clinical complications observed in LRBA-deficient patients. Although 81% of LRBA-deficient patients had normal T-cell counts, 73% had reduced regulatory T (Treg) cell numbers. Most LRBA-deficient patients had low B-cell subset counts, mainly in switched memory B cells (80%) and plasmablasts (92%), with a defective specific antibody response in 67%. Of the 22 patients, 3 are deceased, 2 were treated successfully with hematopoietic stem cell transplantation, 7 are receiving immunoglobulin replacement, and 15 are receiving immunosuppressive treatment with systemic corticosteroids alone or in combination with steroid-sparing agents.This report describes the largest cohort of patients with LRBA deficiency and offers guidelines for physicians to identify LRBA deficiency, supporting appropriate clinical management.CONCLUSIONThis report describes the largest cohort of patients with LRBA deficiency and offers guidelines for physicians to identify LRBA deficiency, supporting appropriate clinical management. |
Author | Seneviratne, Suranjith Feuchtinger, Tobias Burns, Siobhan Jordan, Michael Jung, Sophie Noriko, Mitsuiki Kanariou, Maria Stepensky, Polina Worth, Austen J.J. Blessing, Jacob Van de Veerdonk, Frank Rezaei, Nima Grimbacher, Bodo Belohradsky, Bernd H. Revel-Vilk, Shoshana Speckmann, Carsten Schmitt-Graeff, Annette Gámez-Díaz, Laura Bakhtiar, Shahrzad Morio, Tomohiro August, Dietrich Seidel, Markus G. |
Author_xml | – sequence: 1 givenname: Laura surname: Gámez-Díaz fullname: Gámez-Díaz, Laura organization: Center for Chronic Immunodeficiency, University Medical Center Freiburg, Freiburg, Germany – sequence: 2 givenname: Dietrich surname: August fullname: August, Dietrich organization: Center for Chronic Immunodeficiency, University Medical Center Freiburg, Freiburg, Germany – sequence: 3 givenname: Polina surname: Stepensky fullname: Stepensky, Polina organization: Pediatric Hematology-Oncology and Bone Marrow Transplantation, Hadassah Hebrew University Hospital, Jerusalem, Israel – sequence: 4 givenname: Shoshana surname: Revel-Vilk fullname: Revel-Vilk, Shoshana organization: Pediatric Hematology-Oncology and Bone Marrow Transplantation, Hadassah Hebrew University Hospital, Jerusalem, Israel – sequence: 5 givenname: Markus G. surname: Seidel fullname: Seidel, Markus G. organization: Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology-Oncology, Medical University Graz, Graz, Austria – sequence: 6 givenname: Mitsuiki surname: Noriko fullname: Noriko, Mitsuiki organization: Department of Pediatrics and Developmental Biology Graduate School of Medical and Dental Sciences Tokyo Medical and Dental University, Tokyo, Japan – sequence: 7 givenname: Tomohiro surname: Morio fullname: Morio, Tomohiro organization: Department of Pediatrics and Developmental Biology Graduate School of Medical and Dental Sciences Tokyo Medical and Dental University, Tokyo, Japan – sequence: 8 givenname: Austen J.J. surname: Worth fullname: Worth, Austen J.J. organization: Department of Immunology, Great Ormond Street Hospital for Children, London, United Kingdom – sequence: 9 givenname: Jacob surname: Blessing fullname: Blessing, Jacob organization: Cincinnati Children's Hospital Medical Center, University of Cincinnati Medical School, Cincinnati, Ohio – sequence: 10 givenname: Frank surname: Van de Veerdonk fullname: Van de Veerdonk, Frank organization: Department of Internal Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands – sequence: 11 givenname: Tobias orcidid: 0000-0003-1509-8103 surname: Feuchtinger fullname: Feuchtinger, Tobias organization: Pediatric Hematology, Oncology and Stem Cell Transplantation, Dr. von Hauner University Children's Hospital, Ludwig-Maximilians-Universität, Munich, Germany – sequence: 12 givenname: Maria surname: Kanariou fullname: Kanariou, Maria organization: Department of Immunology, “Aghia Sophia” Children's Hospital, Athens, Greece – sequence: 13 givenname: Annette surname: Schmitt-Graeff fullname: Schmitt-Graeff, Annette organization: Department of Pathology, University Hospital Freiburg, Freiburg, Germany – sequence: 14 givenname: Sophie surname: Jung fullname: Jung, Sophie organization: Center for Chronic Immunodeficiency, University Medical Center Freiburg, Freiburg, Germany – sequence: 15 givenname: Suranjith surname: Seneviratne fullname: Seneviratne, Suranjith organization: UCL Centre for Immunodeficiency, Royal Free Hospital Foundation Trust, London, United Kingdom – sequence: 16 givenname: Siobhan surname: Burns fullname: Burns, Siobhan organization: UCL Centre for Immunodeficiency, Royal Free Hospital Foundation Trust, London, United Kingdom – sequence: 17 givenname: Bernd H. surname: Belohradsky fullname: Belohradsky, Bernd H. organization: Division of Immunology and Infectious Disease, University Childrens Hospital Munich, Munich, Germany – sequence: 18 givenname: Nima surname: Rezaei fullname: Rezaei, Nima organization: Research Center for Immunodeficiencies, Children's Medical Center, and the Department of Immunology, School of Medicine Tehran University of Medical Sciences, Tehran, Iran – sequence: 19 givenname: Shahrzad surname: Bakhtiar fullname: Bakhtiar, Shahrzad organization: Division for Stem Cell Transplantation and Immunology, Department for Children and Adolescents Medicine, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany – sequence: 20 givenname: Carsten surname: Speckmann fullname: Speckmann, Carsten organization: Center for Chronic Immunodeficiency, University Medical Center Freiburg, Freiburg, Germany – sequence: 21 givenname: Michael surname: Jordan fullname: Jordan, Michael organization: Cincinnati Children's Hospital Medical Center, University of Cincinnati Medical School, Cincinnati, Ohio – sequence: 22 givenname: Bodo surname: Grimbacher fullname: Grimbacher, Bodo email: bodo.grimbacher@uniklinik-freiburg.de organization: Center for Chronic Immunodeficiency, University Medical Center Freiburg, Freiburg, Germany |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26768763$$D View this record in MEDLINE/PubMed https://hal.science/hal-03417878$$DView record in HAL |
BookMark | eNqFkltvEzEQhS1URC_wB3hAK_HSPmzwZdcXhJBCBRQpEoiGZ8vrnSVON3awNxH593ibFqRItE-Wre8cz8yZU3TkgweEXhI8IZjwN8vJ0lg3oZjUE6wmmNZP0AnBSpRc0voInWCsSMlFpY7RaUpLnO9MqmfomHLBpeDsBM3nCyjg9wC-hbZYL8CHYbeGInTF7Nt1GSGtg09uC0UD7ieUvbuBwni7CLFYxzCA88X57PuH6UXRQuesA293z9HTzvQJXtydZ-jHp4_zy6ty9vXzl8vprLSci6FUopOK2LbuSNV1itdM0oaaRjUVB8It6YSkVUOINEq0NRDRMIwts7JrqRAVO0MXe9-F6fU6upWJOx2M01fTmR7fMKuIkEJuSWbP92yu-tcG0qBXLlnoe-MhbJImglMmqvrW9lEUS0EJZxl9fYAuwyb63HSmap7HzZnK1Ks7atOsoP1b6n0MGZB7wMaQUoROWzeYwQU_RON6TbAeE9dLPSaux8Q1VjonnqX0QHrv_qDo3V4EOZ2tg6jTbXLQugh20G1wD8vfH8ht77yzpr-BHaR_I9CJaqyvxz0c15DUmDBe02zw9v8Gj_3-B5Mn6M0 |
CitedBy_id | crossref_primary_10_3390_biology11040612 crossref_primary_10_1038_cti_2017_20 crossref_primary_10_1016_j_jaci_2017_06_009 crossref_primary_10_1007_s10875_017_0401_y crossref_primary_10_1111_bjh_18497 crossref_primary_10_1111_pai_12735 crossref_primary_10_1111_pai_12734 crossref_primary_10_3389_fimmu_2021_606099 crossref_primary_10_1186_s40164_021_00229_y crossref_primary_10_3389_fimmu_2018_02397 crossref_primary_10_3389_fimmu_2019_00998 crossref_primary_10_3389_fimmu_2021_692219 crossref_primary_10_1007_s42000_020_00257_z crossref_primary_10_3389_fimmu_2021_671755 crossref_primary_10_1007_s10875_024_01803_9 crossref_primary_10_1016_j_jaci_2021_04_005 crossref_primary_10_3389_fimmu_2020_574569 crossref_primary_10_1002_pbc_27260 crossref_primary_10_1007_s10875_018_0515_x crossref_primary_10_1177_03946320221125591 crossref_primary_10_1182_blood_2021013496 crossref_primary_10_1016_j_clim_2019_04_011 crossref_primary_10_1016_j_jaci_2018_08_026 crossref_primary_10_35366_102982 crossref_primary_10_1007_s10875_016_0320_3 crossref_primary_10_3389_fimmu_2021_786516 crossref_primary_10_1007_s10875_017_0446_y crossref_primary_10_1007_s10875_019_0594_3 crossref_primary_10_2337_db17_0040 crossref_primary_10_3389_fimmu_2024_1386260 crossref_primary_10_3389_fimmu_2020_01950 crossref_primary_10_1111_imr_12721 crossref_primary_10_3389_fimmu_2024_1409434 crossref_primary_10_1016_j_jaci_2019_12_896 crossref_primary_10_1182_blood_2017_11_814244 crossref_primary_10_1513_AnnalsATS_201601_079OC crossref_primary_10_1007_s12016_018_8689_9 crossref_primary_10_1182_blood_2021014323 crossref_primary_10_1073_pnas_1901407116 crossref_primary_10_3390_cells11213353 crossref_primary_10_14785_lymphosign_2018_0011 crossref_primary_10_1016_j_jaci_2017_07_023 crossref_primary_10_1080_08820139_2020_1833029 crossref_primary_10_1186_s13023_017_0682_5 crossref_primary_10_1073_pnas_2202125119 crossref_primary_10_3389_fped_2020_599283 crossref_primary_10_1007_s10875_024_01770_1 crossref_primary_10_1007_s10875_017_0444_0 crossref_primary_10_1016_j_clim_2018_10_005 crossref_primary_10_3389_fped_2017_00049 crossref_primary_10_3389_fimmu_2020_01775 crossref_primary_10_12688_f1000research_21553_1 crossref_primary_10_1159_000503997 crossref_primary_10_1016_j_jaip_2019_11_039 crossref_primary_10_1186_s12887_023_04182_z crossref_primary_10_1016_j_coi_2017_07_014 crossref_primary_10_1080_16078454_2022_2058736 crossref_primary_10_3389_fimmu_2021_619246 crossref_primary_10_1016_j_jaci_2018_10_026 crossref_primary_10_3389_fped_2019_00461 crossref_primary_10_1146_annurev_immunol_093019_124513 crossref_primary_10_1016_j_jaip_2019_04_011 crossref_primary_10_1172_JCI85647 crossref_primary_10_1016_j_clim_2016_03_006 crossref_primary_10_1038_s41467_024_53553_2 crossref_primary_10_1002_jcp_26772 crossref_primary_10_3389_fimmu_2018_00966 crossref_primary_10_1172_JCI129301 crossref_primary_10_3389_fped_2018_00121 crossref_primary_10_1007_s00431_018_3171_5 crossref_primary_10_3389_fimmu_2018_00720 crossref_primary_10_1007_s11926_019_0854_5 crossref_primary_10_1016_j_iac_2020_03_003 crossref_primary_10_3389_fped_2019_00353 crossref_primary_10_1111_sji_12922 crossref_primary_10_1038_s41390_019_0600_8 crossref_primary_10_1002_mgg3_1216 crossref_primary_10_3389_fimmu_2022_830961 crossref_primary_10_1007_s40272_016_0175_3 crossref_primary_10_3389_fimmu_2018_02012 crossref_primary_10_1080_08820139_2018_1446978 crossref_primary_10_1016_j_revmed_2016_10_388 crossref_primary_10_1016_j_jaci_2021_07_015 crossref_primary_10_1053_j_gastro_2016_12_016 crossref_primary_10_1016_j_jaci_2017_01_004 crossref_primary_10_1038_icb_2017_65 crossref_primary_10_1007_s10875_018_0524_9 crossref_primary_10_1038_s41467_023_38810_0 crossref_primary_10_17533_udea_acbi_v42n112a05 crossref_primary_10_1016_j_jecr_2022_100108 crossref_primary_10_1089_ped_2022_0088 crossref_primary_10_1016_j_jaip_2016_08_005 crossref_primary_10_1038_srep36568 crossref_primary_10_1016_j_jaip_2016_08_004 crossref_primary_10_3389_fimmu_2020_608024 crossref_primary_10_1186_s13023_022_02249_1 crossref_primary_10_1136_jmedgenet_2015_103690 crossref_primary_10_1007_s10875_022_01358_7 crossref_primary_10_1038_icb_2017_52 crossref_primary_10_1038_icb_2017_50 crossref_primary_10_1080_15513815_2022_2088912 crossref_primary_10_1016_j_coi_2021_05_010 crossref_primary_10_1016_j_imlet_2017_08_021 crossref_primary_10_2174_1871530319666190807161546 crossref_primary_10_1111_all_15331 crossref_primary_10_3389_fimmu_2017_00964 crossref_primary_10_1136_bcr_2022_250243 crossref_primary_10_3390_jcm10204729 crossref_primary_10_12998_wjcc_v9_i21_5873 crossref_primary_10_1038_s41584_024_01184_8 crossref_primary_10_1016_S1773_035X_23_00029_1 crossref_primary_10_3389_fped_2021_697706 crossref_primary_10_1097_MPH_0000000000001292 crossref_primary_10_1016_j_clim_2023_109302 crossref_primary_10_3390_ijms26062653 crossref_primary_10_1038_s41598_017_08543_4 crossref_primary_10_3389_fimmu_2021_806043 crossref_primary_10_1099_jmmcr_0_005167 crossref_primary_10_1080_09553002_2019_1577570 crossref_primary_10_3390_cancers15010081 crossref_primary_10_3389_fimmu_2017_00052 crossref_primary_10_1038_s41423_020_00626_z crossref_primary_10_1172_jci_insight_122728 crossref_primary_10_1016_j_jaip_2020_10_057 crossref_primary_10_1097_ACI_0000000000000431 crossref_primary_10_1007_s13312_021_2175_9 crossref_primary_10_3389_fimmu_2022_881206 crossref_primary_10_3389_fped_2020_00042 crossref_primary_10_1016_j_jaci_2017_05_022 crossref_primary_10_1007_s00247_022_05361_3 crossref_primary_10_3389_fimmu_2021_704261 crossref_primary_10_1111_liv_15615 crossref_primary_10_1016_j_iac_2020_04_001 crossref_primary_10_3389_fped_2016_00098 crossref_primary_10_1080_07357907_2022_2153860 crossref_primary_10_1182_blood_2016_10_745174 crossref_primary_10_1016_j_jaip_2018_12_017 crossref_primary_10_1097_MPH_0000000000001708 crossref_primary_10_2174_1871530321666211209162834 crossref_primary_10_3389_fimmu_2024_1351076 crossref_primary_10_1007_s10875_020_00799_2 crossref_primary_10_3389_fimmu_2020_00338 crossref_primary_10_1007_s10875_019_00640_5 crossref_primary_10_1016_j_jaci_2023_03_026 crossref_primary_10_1038_s41385_021_00398_3 crossref_primary_10_1007_s10875_021_01177_2 crossref_primary_10_1182_blood_2016_04_712612 crossref_primary_10_15252_embr_201643689 crossref_primary_10_1097_MPH_0000000000002120 crossref_primary_10_1186_s40348_023_00167_1 crossref_primary_10_1136_gutjnl_2019_319850 crossref_primary_10_5812_ijp_84691 crossref_primary_10_1016_j_coi_2021_06_011 crossref_primary_10_1182_blood_2019000929 crossref_primary_10_3389_fped_2019_00295 crossref_primary_10_1097_ACI_0000000000000590 crossref_primary_10_14785_lymphosign_2023_0004 crossref_primary_10_1016_j_jaip_2019_06_011 crossref_primary_10_1002_ajmg_a_38480 crossref_primary_10_3389_fimmu_2018_01423 crossref_primary_10_1136_thoraxjnl_2021_217260 crossref_primary_10_1186_s12969_019_0388_4 crossref_primary_10_3389_fped_2021_662645 crossref_primary_10_1182_bloodadvances_2020002793 crossref_primary_10_1182_blood_2017_06_741033 crossref_primary_10_1080_08820139_2020_1770784 crossref_primary_10_1016_j_bj_2021_04_005 crossref_primary_10_1007_s00439_020_02131_9 crossref_primary_10_1038_s41525_021_00263_z crossref_primary_10_1097_MOP_0000000000001331 crossref_primary_10_1007_s11096_023_01678_7 crossref_primary_10_1212_WNL_0000000000207609 crossref_primary_10_1007_s10875_023_01582_9 crossref_primary_10_1007_s10875_023_01604_6 crossref_primary_10_1016_j_jaip_2019_02_018 crossref_primary_10_1016_j_jaci_2018_02_055 crossref_primary_10_1007_s10875_019_00677_6 crossref_primary_10_1111_pai_14179 crossref_primary_10_1007_s10875_024_01759_w crossref_primary_10_3389_fimmu_2022_944810 crossref_primary_10_1002_ppul_25373 crossref_primary_10_1172_JCI90831 crossref_primary_10_14785_lymphosign_2019_0015 crossref_primary_10_1016_j_htct_2022_03_003 crossref_primary_10_1016_j_humimm_2018_10_015 crossref_primary_10_1038_s41586_024_08346_4 crossref_primary_10_1111_cei_13600 crossref_primary_10_1007_s10620_020_06540_8 crossref_primary_10_1186_s40348_021_00114_y crossref_primary_10_1016_j_jaci_2023_08_004 crossref_primary_10_3389_fimmu_2019_02742 crossref_primary_10_1159_000453263 crossref_primary_10_1016_j_aller_2019_07_011 |
Cites_doi | 10.1038/nm.3746 10.1016/S0022-3476(97)70200-2 10.1016/j.jaci.2012.07.035 10.1186/ar2992 10.1016/j.ajhg.2012.04.015 10.1016/j.clim.2009.10.002 10.1111/tra.12069 10.1016/j.jaci.2012.05.043 10.1097/MIB.0000000000000266 10.1016/j.jaci.2014.10.019 10.1016/j.jaci.2014.10.048 10.1016/j.clim.2015.04.007 10.1016/B978-0-12-385991-4.00002-7 10.1126/science.aaa1663 |
ContentType | Journal Article |
Copyright | 2015 American Academy of Allergy, Asthma & Immunology American Academy of Allergy, Asthma & Immunology Copyright © 2015 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved. Copyright Elsevier Limited Jan 2016 Distributed under a Creative Commons Attribution 4.0 International License |
Copyright_xml | – notice: 2015 American Academy of Allergy, Asthma & Immunology – notice: American Academy of Allergy, Asthma & Immunology – notice: Copyright © 2015 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved. – notice: Copyright Elsevier Limited Jan 2016 – notice: Distributed under a Creative Commons Attribution 4.0 International License |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7SS 7T5 H94 K9. NAPCQ 7X8 1XC VOOES |
DOI | 10.1016/j.jaci.2015.09.025 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Entomology Abstracts (Full archive) Immunology Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic Hyper Article en Ligne (HAL) Hyper Article en Ligne (HAL) (Open Access) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Entomology Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Immunology Abstracts MEDLINE - Academic |
DatabaseTitleList | AIDS and Cancer Research Abstracts Entomology Abstracts MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1097-6825 |
EndPage | 230 |
ExternalDocumentID | oai_HAL_hal_03417878v1 3922004361 26768763 10_1016_j_jaci_2015_09_025 S0091674915013652 1_s2_0_S0091674915013652 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: Bundesministerium für Bildung und Forschung grantid: 01E01303; 012X1306F; 8000805-3; 01GM1517C; 01GM1111B funderid: http://dx.doi.org/10.13039/501100002347 |
GroupedDBID | --- --K --M -~X .1- .55 .FO .GJ .XZ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 354 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8F7 8FE 8FH 8P~ 9JM AAAJQ AABNK AAEDT AAEDW AAFWJ AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AARKO AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABJNI ABLJU ABMAC ABMZM ABOCM ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADFRT ADMUD ADNMO ADVLN ADXHL AEBSH AEIPS AEKER AENEX AEUPX AFFNX AFJKZ AFPUW AFRAH AFRHN AFTJW AFXIZ AGCQF AGEKW AGHFR AGQPQ AGUBO AGYEJ AHHHB AHMBA AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV BPHCQ BVXVI C45 CAG CJTIS COF CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HDU HMK HMO HVGLF HZ~ IHE J1W J5H K-O KOM L7B LK8 LUGTX M27 M41 MO0 N4W N9A O-L O9- O9~ OAUVE OBH ODZKP OHH OHT OK0 OK1 OVD OZT P-8 P-9 P2P PC. PQQKQ PROAC Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SJN SPCBC SSH SSI SSZ T5K TEORI TWZ UGJ UNMZH UV1 WH7 WOW WUQ X7M XFW YOC YQI YQJ Z5R ZGI ZXP ZY1 ~02 ~G- ~KM AACTN RIG AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM 7SS 7T5 H94 K9. NAPCQ 7X8 1XC VOOES |
ID | FETCH-LOGICAL-c667t-97f891cd5f14ff965382b2ab9b46e16c1f7824b118a97d5e17b300c3c8fd27743 |
IEDL.DBID | .~1 |
ISSN | 0091-6749 1097-6825 |
IngestDate | Wed Jun 04 07:14:11 EDT 2025 Fri Jul 11 06:48:10 EDT 2025 Fri Jul 11 00:55:32 EDT 2025 Wed Aug 13 10:34:14 EDT 2025 Mon Jul 21 06:07:38 EDT 2025 Tue Jul 01 00:47:14 EDT 2025 Thu Apr 24 23:02:30 EDT 2025 Sun Apr 06 06:53:23 EDT 2025 Wed Apr 02 07:43:50 EDT 2025 Tue Aug 26 19:48:29 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | ALPS-Ph ITP LRBA LPS-responsive beige-like anchor protein Treg IBD hypogammaglobulinemia ALPS CVID autoimmunity common variable Immunodeficiency enteropathy primary immunodeficiency IPEX lymphoproliferation HSCT Autoimmune lymphoproliferative syndrome of undetermined genetic cause Idiopathic thrombocytopenic purpura Inflammatory bowel disease Autoimmune lymphoproliferative syndrome Regulatory T Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome Hematopoietic stem cell transplantation |
Language | English |
License | Copyright © 2015 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved. Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c667t-97f891cd5f14ff965382b2ab9b46e16c1f7824b118a97d5e17b300c3c8fd27743 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0003-1509-8103 0000-0002-7925-1077 0000-0002-9259-1025 |
OpenAccessLink | https://hal.science/hal-03417878 |
PMID | 26768763 |
PQID | 1756938639 |
PQPubID | 105664 |
PageCount | 8 |
ParticipantIDs | hal_primary_oai_HAL_hal_03417878v1 proquest_miscellaneous_1762374574 proquest_miscellaneous_1760872163 proquest_journals_1756938639 pubmed_primary_26768763 crossref_citationtrail_10_1016_j_jaci_2015_09_025 crossref_primary_10_1016_j_jaci_2015_09_025 elsevier_sciencedirect_doi_10_1016_j_jaci_2015_09_025 elsevier_clinicalkeyesjournals_1_s2_0_S0091674915013652 elsevier_clinicalkey_doi_10_1016_j_jaci_2015_09_025 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2016-01-01 |
PublicationDateYYYYMMDD | 2016-01-01 |
PublicationDate_xml | – month: 01 year: 2016 text: 2016-01-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: St. Louis |
PublicationTitle | Journal of allergy and clinical immunology |
PublicationTitleAlternate | J Allergy Clin Immunol |
PublicationYear | 2016 |
Publisher | Elsevier Inc Elsevier Limited Elsevier |
Publisher_xml | – name: Elsevier Inc – name: Elsevier Limited – name: Elsevier |
References | Revel-Vilk, Fischer, Keller, Nabhani, Gamez-Diaz, Rensing-Ehl (bib8) 2015; 159 Park, Levinson (bib11) 2010; 134 Charbonnier, Janssen, Chou, Ohsumi, Keles, Hsu (bib6) 2015; 135 Beck, Morbach, Beer, Stenzel, Tappe, Gattenlohner (bib9) 2010; 12 Yong, Thaventhiran, Grimbacher (bib12) 2011; 111 Cullinane, Schaffer, Huizing (bib1) 2013; 14 Alangari, Alsultan, Adly, Massaad, Kiani, Aljebreen (bib3) 2012; 130 Lo, Zhang, Lu, Zheng, Zhang, Kanellopoulou (bib13) 2015; 349 Lopez-Herrera, Tampella, Pan-Hammarstrom, Herholz, Trujillo-Vargas, Phadwal (bib2) 2012; 90 Seidel, Hirschmugl, Gamez-Diaz, Schwinger, Serwas, Deutschmann (bib7) 2015; 135 Serwas, Kansu, Santos-Valente, Kuloglu, Demir, Yaman (bib4) 2015; 21 Comans-Bitter, de Groot, van den Beemd, Neijens, Hop, Groeneveld (bib10) 1997; 130 Burns, Zenner, Plagnol, Curtis, Mok, Eisenhut (bib5) 2012; 130 Schubert, Bode, Kenefeck, Hou, Wing, Kennedy (bib14) 2014; 20 Cullinane (10.1016/j.jaci.2015.09.025_bib1) 2013; 14 Revel-Vilk (10.1016/j.jaci.2015.09.025_bib8) 2015; 159 Beck (10.1016/j.jaci.2015.09.025_bib9) 2010; 12 Park (10.1016/j.jaci.2015.09.025_bib11) 2010; 134 Yong (10.1016/j.jaci.2015.09.025_bib12) 2011; 111 Schubert (10.1016/j.jaci.2015.09.025_bib14) 2014; 20 Burns (10.1016/j.jaci.2015.09.025_bib5) 2012; 130 Lo (10.1016/j.jaci.2015.09.025_bib13) 2015; 349 Charbonnier (10.1016/j.jaci.2015.09.025_bib6) 2015; 135 Seidel (10.1016/j.jaci.2015.09.025_bib7) 2015; 135 Serwas (10.1016/j.jaci.2015.09.025_bib4) 2015; 21 Lopez-Herrera (10.1016/j.jaci.2015.09.025_bib2) 2012; 90 Alangari (10.1016/j.jaci.2015.09.025_bib3) 2012; 130 Comans-Bitter (10.1016/j.jaci.2015.09.025_bib10) 1997; 130 |
References_xml | – volume: 159 start-page: 84 year: 2015 end-page: 92 ident: bib8 article-title: Autoimmune lymphoproliferative syndrome-like disease in patients with LRBA mutation publication-title: Clin Immunol – volume: 130 start-page: 1428 year: 2012 end-page: 1432 ident: bib5 article-title: LRBA gene deletion in a patient presenting with autoimmunity without hypogammaglobulinemia publication-title: J Allergy Clin Immunol – volume: 130 start-page: 388 year: 1997 end-page: 393 ident: bib10 article-title: Immunophenotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations publication-title: J Pediatr – volume: 111 start-page: 47 year: 2011 end-page: 107 ident: bib12 article-title: “A rose is a rose is a rose,” but CVID is Not CVID common variable immune deficiency (CVID), what do we know in 2011? publication-title: Adv Immunol – volume: 134 start-page: 97 year: 2010 end-page: 103 ident: bib11 article-title: Granulomatous-lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID) publication-title: Clin Immunol – volume: 135 start-page: 1384 year: 2015 end-page: 1390 ident: bib7 article-title: Long-term remission after allogeneic hematopoietic stem cell transplantation in LPS-responsive beige-like anchor (LRBA) deficiency publication-title: J Allergy Clin Immunol – volume: 12 start-page: R74 year: 2010 ident: bib9 article-title: Chronic nonbacterial osteomyelitis in childhood: prospective follow-up during the first year of anti-inflammatory treatment publication-title: Arthritis Res Ther – volume: 14 start-page: 749 year: 2013 end-page: 766 ident: bib1 article-title: The BEACH is hot: a LYST of emerging roles for BEACH-domain containing proteins in human disease publication-title: Traffic – volume: 90 start-page: 986 year: 2012 end-page: 1001 ident: bib2 article-title: Deleterious mutations in LRBA are associated with a syndrome of immune deficiency and autoimmunity publication-title: Am J Hum Genet – volume: 135 start-page: 217 year: 2015 end-page: 227.e9 ident: bib6 article-title: Regulatory T-cell deficiency and immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like disorder caused by loss-of-function mutations in LRBA publication-title: J Allergy Clin Immunol – volume: 130 start-page: 481 year: 2012 end-page: 488.e2 ident: bib3 article-title: LPS-responsive beige-like anchor (LRBA) gene mutation in a family with inflammatory bowel disease and combined immunodeficiency publication-title: J Allergy Clin Immunol – volume: 21 start-page: 40 year: 2015 end-page: 47 ident: bib4 article-title: Atypical manifestation of LRBA deficiency with predominant IBD-like phenotype publication-title: Inflamm Bowel Dis – volume: 349 start-page: 436 year: 2015 end-page: 440 ident: bib13 article-title: AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy publication-title: Science – volume: 20 start-page: 1410 year: 2014 end-page: 1416 ident: bib14 article-title: Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations publication-title: Nat Med – volume: 20 start-page: 1410 year: 2014 ident: 10.1016/j.jaci.2015.09.025_bib14 article-title: Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations publication-title: Nat Med doi: 10.1038/nm.3746 – volume: 130 start-page: 388 year: 1997 ident: 10.1016/j.jaci.2015.09.025_bib10 article-title: Immunophenotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations publication-title: J Pediatr doi: 10.1016/S0022-3476(97)70200-2 – volume: 130 start-page: 1428 year: 2012 ident: 10.1016/j.jaci.2015.09.025_bib5 article-title: LRBA gene deletion in a patient presenting with autoimmunity without hypogammaglobulinemia publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2012.07.035 – volume: 12 start-page: R74 year: 2010 ident: 10.1016/j.jaci.2015.09.025_bib9 article-title: Chronic nonbacterial osteomyelitis in childhood: prospective follow-up during the first year of anti-inflammatory treatment publication-title: Arthritis Res Ther doi: 10.1186/ar2992 – volume: 90 start-page: 986 year: 2012 ident: 10.1016/j.jaci.2015.09.025_bib2 article-title: Deleterious mutations in LRBA are associated with a syndrome of immune deficiency and autoimmunity publication-title: Am J Hum Genet doi: 10.1016/j.ajhg.2012.04.015 – volume: 134 start-page: 97 year: 2010 ident: 10.1016/j.jaci.2015.09.025_bib11 article-title: Granulomatous-lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID) publication-title: Clin Immunol doi: 10.1016/j.clim.2009.10.002 – volume: 14 start-page: 749 year: 2013 ident: 10.1016/j.jaci.2015.09.025_bib1 article-title: The BEACH is hot: a LYST of emerging roles for BEACH-domain containing proteins in human disease publication-title: Traffic doi: 10.1111/tra.12069 – volume: 130 start-page: 481 year: 2012 ident: 10.1016/j.jaci.2015.09.025_bib3 article-title: LPS-responsive beige-like anchor (LRBA) gene mutation in a family with inflammatory bowel disease and combined immunodeficiency publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2012.05.043 – volume: 21 start-page: 40 year: 2015 ident: 10.1016/j.jaci.2015.09.025_bib4 article-title: Atypical manifestation of LRBA deficiency with predominant IBD-like phenotype publication-title: Inflamm Bowel Dis doi: 10.1097/MIB.0000000000000266 – volume: 135 start-page: 217 year: 2015 ident: 10.1016/j.jaci.2015.09.025_bib6 article-title: Regulatory T-cell deficiency and immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like disorder caused by loss-of-function mutations in LRBA publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2014.10.019 – volume: 135 start-page: 1384 year: 2015 ident: 10.1016/j.jaci.2015.09.025_bib7 article-title: Long-term remission after allogeneic hematopoietic stem cell transplantation in LPS-responsive beige-like anchor (LRBA) deficiency publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2014.10.048 – volume: 159 start-page: 84 year: 2015 ident: 10.1016/j.jaci.2015.09.025_bib8 article-title: Autoimmune lymphoproliferative syndrome-like disease in patients with LRBA mutation publication-title: Clin Immunol doi: 10.1016/j.clim.2015.04.007 – volume: 111 start-page: 47 year: 2011 ident: 10.1016/j.jaci.2015.09.025_bib12 article-title: “A rose is a rose is a rose,” but CVID is Not CVID common variable immune deficiency (CVID), what do we know in 2011? publication-title: Adv Immunol doi: 10.1016/B978-0-12-385991-4.00002-7 – volume: 349 start-page: 436 year: 2015 ident: 10.1016/j.jaci.2015.09.025_bib13 article-title: AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy publication-title: Science doi: 10.1126/science.aaa1663 |
SSID | ssj0009389 |
Score | 2.586252 |
Snippet | LPS-responsive beige-like anchor protein (LRBA) deficiency is a primary immunodeficiency caused by biallelic mutations in LRBA that abolish LRBA protein... Background LPS-responsive beige-like anchor protein (LRBA) deficiency is a primary immunodeficiency caused by biallelic mutations in LRBA that abolish LRBA... Background LPS-responsive beige-like anchor protein (LRBA) deficiency is a primary immunodeficiency caused by biallelic mutations inLRBAthat abolish LRBA... |
SourceID | hal proquest pubmed crossref elsevier |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 223 |
SubjectTerms | Adaptor Proteins, Signal Transducing - deficiency Adaptor Proteins, Signal Transducing - genetics Adaptor Proteins, Signal Transducing - metabolism Adolescent Allergy and Immunology Apoptosis autoimmunity B-Lymphocytes - immunology Child Child, Preschool common variable Immunodeficiency enteropathy Female Genotype & phenotype Hematopoietic Stem Cell Transplantation Humans hypogammaglobulinemia Immunologic Deficiency Syndromes - drug therapy Immunologic Deficiency Syndromes - immunology Immunologic Deficiency Syndromes - metabolism Immunologic Deficiency Syndromes - therapy Immunosuppressive Agents - therapeutic use Infant Infections Inflammatory bowel disease Kinases Life Sciences LPS-responsive beige-like anchor protein lymphoproliferation Male Mutation Patients Pharmaceutical sciences Phenotype primary immunodeficiency Protein expression Proteins Rodents Siblings T-Lymphocytes - immunology |
Title | The extended phenotype of LPS-responsive beige-like anchor protein (LRBA) deficiency |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0091674915013652 https://www.clinicalkey.es/playcontent/1-s2.0-S0091674915013652 https://dx.doi.org/10.1016/j.jaci.2015.09.025 https://www.ncbi.nlm.nih.gov/pubmed/26768763 https://www.proquest.com/docview/1756938639 https://www.proquest.com/docview/1760872163 https://www.proquest.com/docview/1762374574 https://hal.science/hal-03417878 |
Volume | 137 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIiEuiDeBUhnEAYRC7diO4-NSUS2wrRC0Um9WHg5NqZJqd9sjv52ZxNkKURaJYxxPYo_H4y_ON2OAV6XCVVHKIk61NLGqpI5tbmgnznJpZF3rhOKd9w_S6ZH6dKyPN2B3jIUhWmXw_YNP7711KNkJ2tw5bxqK8bVEobcIaYirRX5YKUNW_u7nFc3DymyAwFbEVDsEzgwcr9O8bIjepftcp3Rc9vWL040TYkn-DYL2S9HeXbgTMCSbDM28Bxu-vQ-39sNf8gdwiGPPxt1tRiSujnZaWVez2Zdv8TzQYi89K3zz3cdnzQ_PcPRPujnr8zY0LXs9-_p-8oZVnjJMUHjmQzja-3C4O43D6QlxmaZmGVtTZ1aUla6FqmuLY5ElRZIXtlCpF2kpagQHqsAPjNyaSnthCsl5KcusrhIEhfIRbLZd658Ak6oywpfoN1FCeW55YfCxJlOVz3niIxCj2lwZUovTCRdnbuSQnTpStSNVO24dqjqCtyuZ8yGxxtrachwNN4aMopNz6PfXSpnrpPwizNOFE26ROO7-sKUI9EryN3P85xtfoqmsOkS5u6eTmaMyjngBvWN2KSLYGi3JXbXE6BRtFQFjBC9Wt3Gu0w-cvPXdBdVJeUbZluTaOok0ShsVwePBSlfNSVL8uMQF5el_9u4Z3MarsAO1BZvL-YV_jphsWWz3k24bbk4-fp4e_AJi7C-0 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb9MwELZGJwEviN9kDDCIBxCKZsd2HD-WialjaYWgk_Zm5YfDsk3J1Hb7-7lrnEyIUSReE1_rnM_nL853nwl5X0hYFYXIw1gJHcpSqNBkGnfiDBNaVJWKsN55Oosnx_LriTrZIvt9LQzSKn3u73L6Olv7K3vem3uXdY01vgYp9AYgDXK1IA9vozqVGpHt8eHRZHajvSuSDgUbHqKBr53paF5nWVEjw0ut5U7xxOzb16c7p0iU_BsKXa9GBw_JAw8j6bjr6SOy5ZrH5O7Ufyh_QuYw_LTf4KbI42pxs5W2FU2__QgXnhl77Wju6p8uvKjPHYUAOG0XdC3dUDf0Q_r98_gjLR2KTGCF5lNyfPBlvj8J_QEKYRHHehUaXSWGF6WquKwqA8ORRHmU5SaXseNxwSvABzKHd4zM6FI5rnPBWCGKpCojwIXiGRk1beNeECpkqbkrIHWChXTMsFzDz-pEli5jkQsI791mC68ujodcXNieRnZm0dUWXW2ZseDqgHwabC47bY2NrUU_GravGoU8ZyH1b7TSt1m5pZ-qS8vtMrLM_hFOAVGD5W8R-c9_fAehMjwQyndPxqnFawwgAyTI5JoHZLePJHvTE61iiFXAjAF5O9yG6Y7fcLLGtVfYJmYJCi6JjW0ioaXSMiDPuygduhPF8H4Ja8rOfz7dG3JvMp-mNj2cHb0k9-GO35DaJaPV4sq9Aoi2yl_7KfgLu-gyZQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+extended+phenotype+of+LPS-responsive+beige-like+anchor+protein+%28LRBA%29+deficiency&rft.jtitle=Journal+of+allergy+and+clinical+immunology&rft.au=G%C3%A1mez-D%C3%ADaz%2C+Laura&rft.au=August%2C+Dietrich&rft.au=Stepensky%2C+Polina&rft.au=Revel-Vilk%2C+Shoshana&rft.date=2016-01-01&rft.pub=Elsevier+Inc&rft.issn=0091-6749&rft.volume=137&rft.issue=1&rft.spage=223&rft.epage=230&rft_id=info:doi/10.1016%2Fj.jaci.2015.09.025&rft.externalDocID=S0091674915013652 |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F00916749%2FS0091674915X00029%2Fcov150h.gif |